

Date and Time: *Monday 16th and Tuesday 17th September 2013*
10:00 – 16:30

Minutes: Confirmed

Guideline Development Group Meeting *Diabetes in children and young people guideline update*

Place: *Royal College of Obstetricians and Gynaecologists
London*

Present: Jerry Wales (Chair) (JW) (Present for notes 1 – 16)
 Francesca Annan (FA) (Present for notes 1 – 16)
 Sarah Eaton (SE) (Present for notes 1 – 16)
 Jo Dalton (JD) (Present for notes 1 – 16)
 Julie Edge (JE) (Present for notes 1 – 16)
 Nikhil Gokani (NG) (Present for notes 11 – 16)
 William Lamb (WL) (Present for notes 1 – 16)
 Claire Pesterfield (CP) (Present for notes 1 – 16)
 Andrew Durward (Present for notes 13 – 16)

In attendance:

NCC-WCH staff: Sarah Bailey (SB) Frauke Becker (FB) Zosia Beckles (ZB)		(Present for notes 1 – 16) (Present for notes 13) (Present for notes 9 – 10 and 15-16)
Paul Jacklin (PJ) Juliet Kenny (JK) Hugh McGuire (HM)		(Present for notes 1 – 16) (Present for notes 1 – 16) (Present for notes 9 – 10 and 15-16)
Moira Mugglestone (MM) Stephen Murphy (SM) Katie Webster		(Present for notes 1 – 16) (Present for notes 1 – 16)
NICE attendees: Sarah Dunsdon		(Present for notes 1 – 16)

Observers:

None		
------	--	--

Notes

Day 1

- JW welcomed the group to the seventh meeting of this guideline development group (GDG). Apologies were received from Nikhil Gokani and Jacqueline Double. JW asked the group to introduce themselves for the benefit of the new NCC-WCH technical team members SB and KW.
- JW asked all the GDG members and other attendees to declare any new interests that they had accrued since GDG 6 and reiterate any interests declared previously that were relevant to the meeting agenda.

FA

Personal non-pecuniary:

Spoke at JDRF 'Type 1 diabetes discovery weekend' where sponsorship was provided by commercial sources unknown to FA.

BL

Personal non-pecuniary:

Spoke at JDRF 'Type 1 diabetes discovery weekend' where sponsorship was provided by commercial sources unknown to BL.

SE

Personal non-pecuniary:

Attended further industry funded GP education meetings (other details as declared previously).

No other new declarations of interest were received from the GDG members or the other attendees. It was agreed that no interests declared at the meeting or previously warranted exclusion of any GDG members from discussions of evidence or formulation of recommendations at the meeting.

Declarations are kept on record at the NCC-WCH and will be published in the full guideline.

3. The minutes from GDG 6 were agreed.
4. HM presented the draft review on ketone monitoring to prevent diabetic ketoacidosis in children and young people with type 1 diabetes (the list of excluded studies, the evidence tables, the evidence profiles and the evidence summary). The group had an opportunity discuss the evidence presented.
5. JW led the group through the process of interpreting the evidence and drafting recommendations for ketone monitoring to prevent diabetic ketoacidosis in children and young people with type 1 diabetes. Notes were made live on screen.
6. HM presented the draft review for blood glucose targets for children and young people with type 1 diabetes (the list of excluded studies and the evidence summary). The group had an opportunity discuss the evidence presented.
7. JW led the group through the process of interpreting the evidence and drafting recommendations for blood glucose targets for children and young people with type 1 diabetes. Notes were made live on screen.
8. PJ sought feedback from the group on costs associated with different ketone monitoring strategies to inform the draft health economic model for this topic.
9. MM presented the draft review protocols for retinopathy and nephropathy screening in children and young people with type 1 or type 2 diabetes and hypertension and dyslipidaemia screening in children and young people with type 2 diabetes. The group then discussed the protocols and notes were made live on screen.
10. JK and RF updated the group on future meeting dates.

Day 2

11. HM presented the draft review for weight loss to improve glycaemic control in children and young people with type 2 diabetes (the list of excluded studies, the evidence tables, the evidence profiles and the evidence summary). The group had an opportunity discuss the evidence presented.
12. JW led the group through the process of interpreting the evidence and drafting recommendations for weight loss to improve glycaemic control in children and young people with type 2 diabetes. Notes were made live on screen.
13. FB gave a presentation updating the group about the health economic literature review. FB and PJ then presented the costing work that had been undertaken for the topic of multiple daily injections versus mixed insulin for type 1 diabetes. The group had an opportunity to ask questions and were invited to provide feedback on the draft costs and underlying assumptions to inform further analysis.
14. JK, SM and JE provided feedback on the discussions that took place at the Diabetes oversight group meeting in July.
15. MM presented the draft review protocol for fluid management for children and young people with DKA. The group then discussed the protocols and notes were made live on screen.
16. There were no items of other business and as time permitted JW invited MM to present one further un-scheduled item. MM presented the draft review protocol for and assessments and investigations for children and young people with DKA. The group then

discussed the protocol and notes were made live on screen.

Date, time and venue of the next meeting

Tuesday 22nd October 2013 10:00–16:30 at the Royal College of Obstetricians and Gynaecologists, London